EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...

Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

Novartis on Friday announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

Background 10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body ...

Obesity treatment should start at a young age, he said, because if you have overweight at ages 3-6 years, the likelihood of ...

Although mortality rates are down overall, progress has not been experienced by all women, with racial disparities still seen.

When Tracey Ryan's son, Leigh, was born 13 weeks premature, it was the beginning of a lifetime of hospital visits. Little ...

M: Metastasis; N: Node ... Molecular imaging, including somatostatin receptor scintigraphy but more so PET with specific tracers, such as C 11-5HTP or Ga 68-DOTA octreotate, will improve staging ...

Neumora's lead asset, Navacaprant, shows weak efficacy in phase 2 trial. Read why we are not optimistic about NMRA's ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

For some patients with breast cancer, ctDNA may have the potential to predict disease relapse after they have undergone ...